BioCentury
ARTICLE | Company News

Celtrix news

May 1, 1995 7:00 AM UTC

The Santa Clara, Calif., company announced a series of senior management changes that it said would complete its strategic refocusing following the decision in February to drop ophthalmic development of BetaKine TGF-beta-2. The compound failed to show efficacy in a Phase II trial in age-related macular degeneration (see BioCentury Feb. 13).

CTRX now is focused on applications of SomatoKine in acute nutritional deficiencies associated with trauma; muscle wasting diseases due to long-term illness; and bone and muscle loss due to osteoporosis. It made sense to have a president and CEO with extensive background with the product, said CFO Mary Anne Ribi. SomatoKine will be entering toxicology studies this summer, with Phase I trials slated for early 1996. ...